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Medication Therapy Management Interventions
in Outpatient Settings
A Systematic Review and Meta-analysis
Meera Viswanathan, PhD; Leila C. Kahwati, MD, MPH; Carol E. Golin, MD; Susan J. Blalock, MPH, PhD;
Emmanuel Coker-Schwimmer, MPH; Rachael Posey, MSLS; Kathleen N. Lohr, PhD, MPhil, MA
IMPORTANCE Medication therapy management (MTM) services (also called clinical pharmacy
services) aim to reduce medication-related problems and their downstream outcomes.
OBJECTIVE To assess the effect of MTM interventions among outpatients with chronic
illnesses.
DATA SOURCES MEDLINE, Cochrane Library, and International Pharmaceutical Abstracts
through January 9, 2014.
STUDY SELECTION Two reviewers selected studies with comparators and eligible outcomes of
ambulatory adults.
DATA EXTRACTION AND SYNTHESIS Dual review of titles, abstracts, full-text, extractions, risk
of bias, and strength of evidence grading. We conducted meta-analyses using random-effects
models.
MAIN OUTCOMES AND MEASURES Medication-related problems, morbidity, mortality, quality
of life, health care use, costs, and harms.
RESULTS Forty-four studies met the inclusion criteria. The evidence was insufficient to
determine the effect of MTM interventions on most evaluated outcomes (eg, drug therapy
problems, adverse drug events, disease-specific morbidity, disease-specific or all-cause
mortality, and harms). The interventions improved a few measures of medication-related
problems and health care use and costs (low strength of evidence) when compared with
usual care. Specifically, MTM interventions improved medication appropriateness (4.9 vs 0.9
points on the medication appropriateness index, P < .001), adherence (approximately 4.6%),
and percentage of patients achieving a threshold adherence level (odds ratios [ORs] ranged
from 0.99 to 5.98) and reduced medication dosing (mean difference, −2.2 doses; 95% CI,
−3.738 to −0.662). Medication therapy management interventions reduced health plan
expenditures on medication costs, although the studies reported wide CIs. For patients with
diabetes mellitus or heart failure, MTM interventions lowered the odds of hospitalization
(diabetes: OR, 0.91 to 0.93 based on type of insurance; adjusted hazard rate for heart failure:
0.55; 95% CI, 0.39 to 0.77) and hospitalization costs (mean differences ranged from
−$363.45 to −$398.98). The interventions conferred no benefit for patient satisfaction and
most measures of health-related quality of life (low strength).
CONCLUSIONS AND RELEVANCE We graded the evidence as insufficient for most outcomes
because of inconsistency and imprecision that stem in part from underlying heterogeneity in
populations and interventions. Medication therapy management interventions may reduce
the frequency of some medication-related problems, including nonadherence, and lower
some health care use and costs, but the evidence is insufficient with respect to improvement
in health outcomes.
JAMA Intern Med. 2015;175(1):76-87. doi:10.1001/jamainternmed.2014.5841




International, Research Triangle Park,
North Carolina (Viswanathan,
Kahwati, Lohr); Cecil G. Sheps Center
for Health Services Research,
University of North Carolina, Chapel
Hill (Golin, Coker-Schwimmer, Posey);
Eshelman School of Pharmacy,
University of North Carolina,
Chapel Hill (Blalock).
Corresponding Author: Meera
Viswanathan, PhD, RTI International,
3040 E Cornwallis Rd, PO Box 12194,





Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
Copyright 2015 American Medical Association. All rights reserved.
U sed appropriately, medications can alleviate distress-ing symptoms, prevent many acute and chronic ill-nesses, and improve patients’ health. However, medi-
cations often are used inappropriately.1-3 In the United States,
adverse drug events led to an estimated 4.5 million ambula-
tory care visits per year during 2005 to 2007.4 In addition to prob-
lems involving adverse drug events, many patients experience
drug therapy problems related to appropriateness (eg, unwar-
ranted polypharmacy, suboptimal regimens), effectiveness (eg,
subtherapeutic doses, therapeutic response not achieved at an
adequate dose), safety (eg, adverse drug effects, drug-drug in-
teractions, and supratherapeutic doses), and adherence.5
Medication therapy management (MTM) is a strategy for
delivering a variety of nondispensing clinical pharmacy ser-
vices to patients and their clinicians; it is a structure for pro-
viding what pharmacists referred to in the early 1990s as phar-
maceutical care.6 Medication therapy management services aim
to optimize therapeutic outcomes by identifying and resolv-
ing drug therapy problems.7 The Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (Public Law
108-173)8 expanded access to MTM services for patients with
certain chronic conditions through Medicare Part D prescrip-
tion drug benefits. In 2005, 11 national pharmacy organiza-
tions established a consensus definition for MTM9; in 2008, a
subset of these organizations established 5 core elements for
an MTM service model.10 These elements include a medica-
tion therapy review, a personal medication record, a medica-
tion action plan, intervention and/or referral for drug therapy
problems, and documentation and follow-up.7 Also by 2008,
Current Procedural Terminology for MTM services (codes 99605,
99606, and 99607) became available and further defined MTM
service-level expectations to include an assessment of drug-
related needs, identification of drug therapy problems, and care
planning and follow-up.11-13
Medication therapy management can be viewed as a pro-
fessionally delivered service with common core features and
goals; specific intervention components may vary based on the
scope and setting of each MTM program. Recent widespread
implementation of MTM services, stemming from perceived
clinical need and access to billing codes, drives an urgent need
for actionable, evidence-based information on its effective-
ness and harms. Our study assessed the effectiveness and
harms of outpatient-based MTM compared with usual care; we
focus on the effect of MTM on drug-therapy problems and their
sequelae, including biomarkers of morbidity, health out-
comes, mortality, patient-centered functioning, quality of life,
satisfaction, and health care use and costs. This article is based
on a systematic evidence report commissioned by the US
Agency for Healthcare Research and Quality (AHRQ) to deter-
mine the effectiveness of outpatient MTM.14
Methods
We developed a protocol for this review.15 A trained librarian,
in consultation with investigators, used numerous terms to
identify MTM-related studies in MEDLINE, the Cochrane Li-
brary, and the International Pharmaceutical Abstracts data-
base (inception through January 9, 2014) (eTable 1 in the
Supplement). We limited searches to English-language and hu-
man-only studies. We manually searched the reference lists
of landmark and background articles for additional relevant
citations. We also searched numerous sources for unpub-
lished literature described in eTable 1 in the Supplement. Fi-
nally, the AHRQ placed a request for unpublished studies in
the Federal Register.
Study Selection
We prespecified required intervention characteristics to re-
duce underlying heterogeneity. We required MTM interven-
tions to include a comprehensive (rather than condition-
specific) medication review, patient-directed education, care
coordination, and opportunity for follow-up. When articles in-
cluded insufficient detail for us to decide on inclusion or ex-
clusion, we contacted the authors for additional information.
We limited our review to ambulatory settings. We anticipated
modest randomized clinical trial (RCT) evidence and there-
fore also included nonrandomized clinical trials (NRCTs), co-
hort studies, and case-control studies. We excluded studies of
MTM services provided within inpatient settings or shortly af-
ter hospital discharge; the goals of therapy and severity of ill-
ness are likely to differ markedly between outpatients and pa-
tients experiencing or recovering from an acute hospital stay.
Two trained members of the research team (M.V., L.C.K.,
C.E.G., S.J.B, E.C.-S., and R.P. performed all functions dis-
cussed) independently reviewed each of the titles, abstracts, and
articles against the inclusion/exclusion criteria (eTable 2 in the
Supplement). Studies marked for possible inclusion by either
reviewer underwent dual, independent full-text review.
Data Extraction and Risk of Bias Assessment
A trained reviewer abstracted information from eligible stud-
ies into structured evidence tables; a second team member re-
viewed all data abstractions for completeness and accuracy.
Reviewers rated the risk of bias independently against prespeci-
fied criteria.16 For RCTs, we relied on the risk-of-bias tool de-
veloped by the Cochrane Collaboration.17 We assessed the
risk of bias of NRCTs using an item bank developed by RTI
International.18
We evaluated RCTs on the adequacy of randomization, al-
location concealment, similarity of groups at baseline, blind-
ing of outcome assessment, attrition, use of intention-to-
treat analysis, method of handling dropouts and missing data,
validity and reliability of outcome measures, and treatment fi-
delity. For NRCTs, we assessed for confounding rather than ad-
equacy of randomization and allocation concealment. We also
evaluated RCTs for confounding attributable to randomiza-
tion failure through biased selection or attrition. We rated the
studies as low, medium, high, or unclear risk of bias.16 Two in-
dependent reviewers assessed the risk of bias for each study
and resolved disagreements by consensus or by consulting a
third member of the team.
Data Synthesis and Analysis
We excluded studies that we deemed at high risk of bias from
our main data analyses, but we included them in sensitivity
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analyses. When we had no other evidence, we included high
risk-of-bias studies in the main analyses.
We conducted meta-analysis when appropriate (≥3 stud-
ies with similar populations, interventions, comparators,
outcomes, and design) using Comprehensive Meta-Analysis
software (Biostat Inc). For all pooled analyses, we used random-
effects models. To determine whether quantitative analyses
were appropriate, we assessed the clinical and methodologic
heterogeneity of the studies under consideration.19 For all
quantitative syntheses, we assessed statistical heterogeneity
in effects between studies by calculating the χ2 statistic and
the I2 statistic (the percentage of total variation across stud-
ies attributable to heterogeneity rather than chance).20 When
relevant, we examined potential sources of heterogeneity from
the risk of bias using sensitivity analysis.
When quantitative analyses were inappropriate, we syn-
thesized the data qualitatively, considering issues of consis-
tency, precision, directness, and risk of bias. Whenever pos-
sible, we computed 95% CIs for outcomes reported in single
studies, but numerous articles did not provide sufficient in-
formation for such computations.
Two reviewers assessed strength of evidence domains for
each outcome and resolved differences by consensus or refer-
ral to a third senior member of the team. We based our grades
on low or medium risk-of-bias RCTs or observational studies
(unless none was available) based on guidance established by
the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) Working Group.21-23 We considered
one of the following grades for each outcome: (1) high (high
confidence that the evidence reflects the true effect), (2) mod-
erate (moderate confidence that the evidence reflects the true
effect; future research may change the estimate), (3) low (low
confidence that the evidence reflects the true effect; further
research is likely to change the estimate), or (4) insufficient
evidence.24
Results
We identified 61 articles (representing 44 studies) that met the
inclusion criteria (Figure 1). The evidence base consisted
of 21 RCTs, 4 NRCTs, and 19 cohort studies. Most studies
compared an MTM intervention with usual care (no MTM
intervention).
Methodologic problems in numerous studies led us to rate
them as having a medium or high risk of bias. Of the 44 studies,
we rated 16 as high risk of bias overall; in these studies, concerns
about randomization failure, confounding, or overall attrition in-
creased the risk of bias for all outcomes. In a few instances, we
rated studies that were otherwise of low or medium risk of bias
as high risk for individual outcomes chiefly because of measure-
ment or detection biases related to the specific outcome. Because
of the underlying heterogeneity of the populations, settings, and
outcomes and the limited number of studies on any single out-
come, we could use only 4 low or medium risk-of-bias studies
in the meta-analysis 25-30 (Figure 2 and Figure 3 and eFigures 1-8
in the Supplement)25-33 and 2 additional high risk-of-bias stud-
ies for sensitivity analysis (eTable 5).34-36
Characteristics of included studies are provided in eTable
3 and eTable 4 in the Supplement. The numbers of partici-
pants analyzed in each study ranged from 10 to 200 722. All
studies used pharmacists to deliver MTM services, specifi-
cally medication review, patient-directed education, care co-
ordination, and opportunity for follow-up. Despite these 4 com-
mon features, MTM interventions differed considerably across
the studies. Of the 44 included studies, 34 were broadly fo-
cused (ie, included a patient population not defined by any spe-
cific clinical condition), and 10 were relatively narrowly fo-
cused on specific patient populations (eg, chronic heart failure,
hypertension, diabetes mellitus, human immunodeficiency vi-
rus, glucocorticoid-induced osteoporosis, or hemodialysis) who
then received comprehensive medication review. Services were
provided face to face in half of the included studies. Included
studies provided interventions in a variety of settings includ-
ing community pharmacies, centralized pharmacies or phar-
macy call centers, outpatient medical clinics, and patients’
homes.
Drug-Related Problems and Biomarkers of Morbidity
Thirty-two studies reported on 1 or more intermediate out-
comes (Table 1). We were unable to pool the results because
too few studies within each design stratum (ie, RCT or co-
hort) were of low or medium risk of bias.
Medication therapy management interventions signifi-
cantly improved medication appropriateness (measured with
a reliable and valid 10-item index of medication appropriate-
ness measuring improved prescribing quality53; 4.9 vs 0.9
points, P < .001).32 For some medications, MTM improved ad-
herence as the percentage of prescribed doses taken (mean im-
provement, approximately 4.6%)41 or percentage of patients
Figure 1. Article Flowchart
2516 Records found through 
database searching after 
duplicates removed












Hand searches of references
Gray literature




2749 Records after duplicates 
removed
2749 Records screened
419 Full-text articles assessed 
for eligibility
61 Articles (44 studies) included 
in qualitative synthesis of 
systematic review
6 Studies included in quantitative 
synthesis of systematic review
2330 Records excluded



















IPA indicates International Pharmaceutical Abstracts; TEP, technical expert
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achieving a threshold adherence level (odds ratio [ORs], 0.99
to 5.98)41 and reduced medication dosing (mean difference,
−2.2 doses; 95% CI, −3.738 to −0.662)48 (Table 1). We had enough
consistency and precision across the body of evidence to as-
sign a low strength-of-evidence grade for these outcomes. Evi-
dence was insufficient to draw any conclusions about effec-
tiveness for the number of drug therapy problems identified
and resolved.
Evidence was insufficient to draw any conclusions about
effectiveness for other intermediate outcomes, including the
effect on anticoagulation, blood pressure, hemoglobin A1c, and
low-density lipoprotein cholesterol. We identified no studies
that addressed the effect of MTM on meeting the goals of
therapy.
Morbidity, Mortality, and Other Patient-Centered Outcomes
Twenty-one studies reported 1 or more patient-centered out-
comes; we were able to synthesize some outcomes quantita-
tively. Specifically, MTM interventions did not improve mea-
sures of health-related quality of life26,31,32 (Table 2 and eTable
5 and eFigures 1-8 in the Supplement), yielding low strength
of evidence for no benefit. For general health-related quality
of life outcomes, meta-analyses of 7 of 8 domains and the 2
component scores (physical health and mental health) showed
no significant benefit from MTM interventions. However, the
vitality domain of the SF-36 showed benefit in meta-analysis
estimates that did not adjust for multiple comparisons. We
graded this outcome as imprecise after correcting for mul-
tiple comparisons and the evidence on vitality as insufficient
(eFigure 5 in the Supplement). The various patient satisfac-
tion outcomes used by studies26,28-30,32,44,58 also showed no
effect from MTM programs (low strength of evidence for no
benefit), although we were unable to pool results because of
the heterogeneity of measures. Evidence was insufficient to
draw conclusions about the effect of MTM on adverse drug
events, gastrointestinal bleeding, mortality, and cognitive and
affective function. No studies evaluated the effect of MTM on
activities of daily living, work or school absenteeism, or pa-
tient and caregiver participation in medical care and decision
making.
Health Care Use Outcomes
Thirty-three studies reported 1 or more outcomes related to the
use of health care, such as the number of emergency depart-
ment visits, number of hospitalizations, costs of laboratory
tests, and total expenditures on medications. In addition to
qualitative syntheses on all outcomes, we were able to pool the
results on the number of outpatient and hospital visits.
Medication therapy management improved health plan
expenditures on medications, but studies had wide
Figure 2. Effect of Medication Therapy Management (MTM) on Mean Number of Outpatient Visits













Sellors et al,27 2003








0.10 (–0.02 to 0.22)
0.00 (–0.14 to 0.14)











Heterogeneity: τ2 = 0; χ22 = 1.18; P = .56, I
2 = 0
Test for overall effect: Z = 1.16; P = .25
Three low or medium risk-of-bias randomized clinical trials of MTM versus
control groups without MTM using the basic arm of the Touchette et al25 study.
Our meta-analysis found no significant difference in the number of outpatient
visits between patients receiving MTM interventions and those receiving usual
care (standardized mean difference, 0.05; 95% CI, −0.03 to 0.13; P = .25).
IMPROVE indicates Impact of Managed Pharmaceutical care on Resource
utilization and Outcomes in Veterans Affairs Medical Center.
Figure 3. Effect of Medication Therapy Management (MTM) on Mean Number of Hospitalizations
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Heterogeneity: τ2 = 0; χ22 = 0.23; P = .89, I
2 = 0
Test for overall effect: Z = 1.68; P = .09
Three low or medium risk-of-bias randomized clinical trials of MTM versus
control groups without MTM, using the basic arm of the Touchette et al25 study.
Our meta-analysis found no significant difference in the number of
hospitalizations between patients receiving MTM and those receiving usual care
(WMD, 0.04; 95% CI, −0.01 to 0.08; P = .09). IMPROVE indicates Impact of
Managed Pharmaceutical care on Resource utilization and Outcomes in
Veterans Affairs Medical Center; WMD, weighted mean difference.
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CIs.27,48,59 The MTM interventions also reduced the risk of
hospitalization (2 studies): the adjusted OR for diabetes
ranged from 0.91 (95% CI, 0.87 to 0.95) to 0.93 (95% CI, 0.88
to 0.98),41 and the adjusted hazard rate for heart failure was
0.55 (95% CI, 0.39 to 0.77).60 Medication therapy manage-
ment also reduced the costs of diabetes-specific hospitaliza-
tion (1 study41) (mean difference, −$363.45 [95% CI,
−$562.00 to −$164.91]) (Table 3). These results are imprecise
or come from cohort studies with inherent limitations, lead-
ing to a judgment of low strength of evidence.
T h r e e R C T s d i d n o t r e d u c e t h e n u m b e r o f
hospitalizations,25-30 although a single cohort study43 found
a lower mean number of inpatient visits for patients accept-
ing MTM (compared with patients refusing MTM). Overall,













Cohort: 1 (582)37 Insufficient High study limitations,
consistency unknown,
indirect, imprecise
Risk difference: 6.1%, P = .06
No. of drug therapy
problems resolved
Cohort: 1 (120)38-40 Insufficient High study limitations,
consistency unknown,
indirect, imprecise
Mean difference (95% CI), −1.00 (1.967 to
−0.033), P = .04
Medication adherence
measured as proportion
of patients adherent to
a threshold amount
of pills taken
RCT: 1 (69)31 Insufficient Medium study
limitations, consistency
unknown, direct, precise
100% of Intervention patients and 88.9% of
controls were adherent (took ≥80% of




Low for benefit High study limitations,
inconsistent, direct,
precise
Two studies with findings in opposite direction;
larger study showing range of ORs for
medication-specific adherence depending on
medication; for comparison of PDP vs controls,
ORs ranged from 0.99 (95% CI, 0.90 to 1.08)
to 1.43 (95% CI, 1.26 to 1.62); for comparison
of MA-PD vs controls, ORs ranged from 1.10
(95% CI, 0.83 to 1.24) to 1.40 (95% CI, 1.29 to
1.52); for clinic-based MTM vs usual care for
adherence to aspirin, ORs of adherence ranged
from 5.981 (95% CI, 0.284 to 126.030; P =
.25) during the intervention to 1.17
determined 1 y after the intervention (95% CI,
0.072 to 18.903; P = .91)
Medication adherence
measured as percentage




Low for benefit for adherence to
treatment for hypertension and
dyslipidemia; insufficient for






Mean difference from small study, −0.040
(95% CI, −0.101 to 0.021; P = .20); larger
study found a small but statistically significant
effect of MTM on adherence to medications for
2 of 5 conditions (4.6% difference for
hypertension [95% CI, 3.211 to 5.989]; 4.7%
for dyslipidemia [95% CI, 2.747 to 6.673]), but
no statistically significant effect for the other








Mean difference, 0.090 (95% CI, −0.076 to
0.256; P = .29
Medication adherence,
miscellaneous measures
RCT: 2 (365)32,45 Insufficient Medium study
limitations, inconsistent,
direct, imprecise
One study showed lesser (but nonsignificant)
improvement in medication-taking risk scores
among the intervention group (−3.47 vs −4.38,
P = .52); second study’s OR was nonsignificant
for better adherence among intervention
group: OR, 1.076 (95% CI, 0.527 to 2.197)
Medication
appropriateness General
Index Scores (range, 0-18;
lower scores are better)
RCT: 1 (208)32 Low for benefit Low study limitations,
consistency unknown,
direct, precise
Improvement in MTM group from score of 17.7
to 13.4 and to 12.8 at 3 and 12 mo,
respectively, whereas in controls these values
were 17.6, 16.5, and 16.7, respectively (P <
.001 for 3- and 12-mo differences)
Medication-specific
appropriateness
RCT: 2 (261)46,47 Insufficient Medium study
limitations, inconsistent,
direct, imprecise
Significant improvement in appropriateness in
the MTM group for some medications: calcium
supplements (percentage of intervention
patients taking it increased from 39% to 56% at
9 mo vs controls, who decreased from 38% to
31%) but not bisphosphonate or estrogen
therapy




Mean difference in doses, −2.2 (95% CI, −3.738
to −0.662)
Goals of therapy 0 NA NA NA
(continued)
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we judged the strength of evidence for mean number of
hospitalizations to be insufficient because of the lack of
consistency across studies.
EvidencewasinsufficientontheeffectofMTMinterventions
on the use of generic medications; measures of medication costs
other than health plan expenditures; number (Figure 2) and costs
of outpatient visits; number and costs of laboratory tests; num-
ber and costs of emergency department visits; and the number
(Figure 3), percentage, and costs of hospitalization for unspeci-
fied conditions, congestive heart failure, or chronic obstructive
pulmonary disease. Frequently, the results were inconsistent for
thesameoutcome;thatis,MTMmayhaveraisedtheuseofhealth
care services in one study and lowered it in another. We could
not interpret these results as either benefits or harms because
studies uniformly evaluated overall change in health care use
rather than whether the increase or decrease in use met the goal
of MTM for individual patients.
Harms of MTM Interventions
Only 1 cohort study (high risk of bias) reported harms, specifi-
c ally on inconvenience resulting from monthly
appointments.66,67 The evidence was insufficient to judge the
effect of MTM on inconvenience. We found no evidence on other
prespecified harms including care fragmentation, patient de-
cisional conflict, patient anxiety, increased adverse drug events,
prescriber confusion, and prescriber dissatisfaction.
Effectiveness of MTM by Intervention Features
We found information from only 1 study for each of 5 inter-
vention features: (1) access of pharmacists to patient records,25









Judgment Findings and Direction of Effect
Biomarkers of Morbidity




Therapeutic INR achieved: 100% vs 16.7%;
P = .048
HbA1c RCT: 2 (102)
31,49 Insufficient Medium study
limitations, inconsistent,
direct, imprecise
One trial with mean difference in HbA1c at 6 mo
of −0.20 (95% CI, −0.93 to 0.53), P = .59; 1
trial with OR, 56.5 (95% CI, 2.81 to 1133.91),




Insufficient High study limitations,
inconsistent, direct,
imprecise
One study with adjusted difference-in-
difference coefficient, 2.44 (95% CI, 1.22 to
4.86), P = .01, at 12 mo for percentage with
HbA1c <7%, but findings not maintained at 24
mo; 1 study with change in mean HbA1c of
−0.02; 95% CI, −0.10 to 0.06; P = .63; and OR,
1.14; 95% CI, 0.97 to 1.35; P = .11, for change
in percentage with HbA1c <7% at 6 mo




OR, 56.00 (95% CI, 5.583 to 561.753), for
percentage of patients at LDL-C goal based on
ATP III criteria at 12 mo
Cohort: 2
(3062)42,50-52
Insufficient High study limitations,
inconsistent, direct,
imprecise
One study with adjusted difference-in-
difference coefficient, 1.95 (95% CI, 0.81 to
4.84), P = .13 for percentage with LDL-C <100
mg/dL at 12 mo; 1 study with OR, 1.39 (95%
CI, 1.160 to 1.670), P < .001 for achieving
LDL-C <100 mg/dL and mean difference in
LDL-C, −4.1 (95% CI, −6.02 to −2.18), P < .001
at 6 mo




OR, 28.88 (95% CI, 5.49 to 151.99), P < .001,
for percentage of patients with SBP and DBP at
goal at 12 mo
Cohort: 2
(2507)42,50-52




One study with adjusted difference-in-
difference coefficient, 0.73 (95% CI, 0.32 to
1.65, P = .45) for percentage achieving BP
<130/80 mm Hg at 12 mo; 1 study found OR,
0.95 (95% CI, 0.81 to 1.13, P = .57) for
percentage with BP <130/80 mm Hg at 6 mo
among patients with both diabetes mellitus and
hypertension and OR, 0.90 (95% CI, 0.73 to
1.10, P = .30) among patients with
hypertension but not diabetes mellitus
Abbreviations: ATP III, Adult Treatment Panel III; BP, blood pressure;
DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; INR, international
normalized ratio; LDL-C, low-density lipoprotein cholesterol; MA-PD, Medicare
Advantage prescription drug plans; MTM, medication therapy management;
NA, not applicable; OR, odds ratio; PDP, Prescription Drug Plans (stand-alone
Part D plans); RCT, randomized clinical trial; SBP, systolic blood pressure.
SI conversion factor: To convert LDL-C to millimoles per liter, multiply by
0.0259.
a Drug therapy problems refer to a range of issues pertaining to drug-related
appropriateness, effectiveness, safety, and adherence.
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(2) intensity of care coordination and follow-up after compre-
hensive medication review,68 (3) community pharmacy vs call
center,69 (4) level of intensity of intervention,70 and (5) type
of payer (private vs Medicaid) (eTable 6 in the Supplement).71
Evidence was insufficient for most outcomes for the first 2 in-
tervention features, with 2 exceptions. First, MTM delivered
by community pharmacists when compared with call center
pharmacists increased the proportion of generics dispensed
(low strength of evidence). Second, enhanced MTM with phar-
macists’ access to patient records reduced the mean number
of adverse drug events; this finding suggested benefit when
compared with basic MTM (low strength of evidence). Evi-
dence was insufficient for all outcomes for the intensity of in-
tervention and type of payer.









Judgment Findings and Direction of Effect




One study with OR, 0.73 to 1.63 (P = NS) for percentage
of patients with an adverse drug event and mean
difference in number of ADEs ranging from −0.06 to 0.28
(all but 1 P value was NS) depending on study arm
comparison (basic MTM or enhanced MTM) and timing of
outcome measurement (3 or 6 mo); 1 study with OR, 0.65
(95% CI, 0.37 to 1.15), P = .14 for percentage of patients
with an adverse drug event at 12 mo
Cognitive and
physical function




No significant differences between study arms on 3
different tests of physical functioning (timed manual
performance, physical performance test, and functional
reach) and 3 different tests of cognitive functioning
(WAIS digit span, WAIS digit symbol, and Randt memory
test) at 6 wk




One study with unadjusted mean difference in CES-D
score, −1.10 (95% CI, −3.8 to 1.62), P = .43, and in self-
rating anxiety score, −0.10 (95% CI, −2.39 to 2.19), P =
.09, at 6 weeks; other study with significant differences
in mean Beck depression and anxiety inventory scores,
but OR, 2.41 (95% CI, 0.60 to 9.63), P = .22 for
percentage of patients achieving depression remission as
defined by Beck depression inventory score <11





OR, 0.59 (95% CI, 0.12 to 2.49), P = .48





One study with OR, 0.5 (95% CI, 0.3 to 0.9); 1 study with
adjusted HR, 0.92 (95% CI, 0.87 to 0.96), P < .001
Gastrointestinal
bleeding events
Cohort: 1 (unclear)57 Insufficient High study limitations,
consistency unknown,
direct, imprecise
RRR, 60%; P = .001
General health-related
quality-of-life domains
other than vitality and
emotional role functioning





Variable mean difference with CIs consistently spanning





RCT: 3 (1169)26,31,32 Insufficient Medium study
limitations, consistent,
direct, imprecise
Vitality: mean difference of 2.797 not corrected for
multiple comparison (95% CI, 0.655 to 4.939), P = .01;
emotional role functioning: mean difference, 5.386 (95%
CI, −7.244 to 18.013); wide CIs
Condition-specific
health-related quality of life
(diabetes mellitus)




Nonsignificant improvement of 0.1 point on a 5-point
scale in the intervention group vs no change in the
control group







No differences on 17 of 21 items of patient satisfaction; 4
statistically significant differences ranged in magnitude
from −0.15 to −0.36, favoring MTM
Activities of daily living 0 NA NA NA
Work or school
absenteeism
0 NA NA NA
Patient and caregiver
participation in medical
care and decision making
0 NA NA NA
Abbreviations: ADEs, adverse drug events; CES-D, Center for Epidemiologic
Studies Depression Scale; HR, hazard ratio; MTM, medication therapy
management; NA, not applicable; NS, not statistically significant; OR, odds ratio;
RCT, randomized clinical trial; RRR, relative risk ratio; WAIS, Wechsler Adult
Intelligence Scale.
a In contrast to drug therapy problem outcomes presented in Table 1, this
outcome refers to actual drug-related adverse events experienced by patients.
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Insufficient High study limitations,
consistency unknown,
direct, imprecise
OR, −0.01 (95% CI, −0.013 to −0.008) to 0.006 (95%
CI, 0.003 to 0.009)
Medication costs:
patient copayments




Mean difference, −$64, variance not calculable
Cohort: 1 (1606)62 Insufficient High study limitations,
consistency unknown,
indirect, precise
Mean difference for MTM vs same country, control
$80.40 (95% CI, $10.43 to $150.37), P = .024; mean
difference for MTM vs different country control,




RCT: 3 (965)27,48,59 Low for benefit Medium study limitations,
consistent, indirect,
imprecise
Mean difference varied from −CaD$34 (95% CI,
−CaD$273.6 to CaD$205.2) to −$293 (95% CI,
−501.5 to −84.5) during 6 mo
NRCT and cohort: 5
(range,
120-200 722)38-41,43,62,63
Insufficient High study limitations,
inconsistent, indirect,
imprecise
Mean difference varied from −$800 over 1 y (95% CI,






Insufficient Medium study limitations,
inconsistent, indirect,
imprecise
Mean difference varies from −$20.16 (95% CI, −$5.78




Insufficient High study limitations,
inconsistent, indirect,
imprecise
Mean difference varied from −$563 (95% CI,






RCT: 2 (996)27,32,33 Insufficient Medium study limitations,
inconsistent, indirect,
imprecise
Differences in mean costs ranging from −CaD$8.1
(95% CI, −CaD$386.72 to CaD$4350.52) to $1947
(95% CI, NR or calculable)
NRCT and cohort: 3
(5300)43,63,65
Insufficient High study limitations,
inconsistent, indirect,
imprecise
Differences in mean costs ranging from −$1039 (95%




RCT: 3 (2208)25-30 Insufficient Medium study limitations,
inconsistent, indirect,
precise
Standardized mean difference, 0.049 (95% CI, −0.034
to 0.133); P = .25; I2 = 0
Cohort: 1 (4500)43 Insufficient High study limitations,
consistency unknown,
indirect, imprecise
Mean difference, 2.48 (95% CI, 1.67 to 3.29), P <
.001
Outpatient costs RCT: 3 (2050)26-30,32,33 Insufficient Medium study limitations,
inconsistent, indirect,
imprecise
Dissimilar measures varying from −$11.92/mo for
costs of health care other than clinic visits to
CaD$1.13 for physician visits/mo
No. of
laboratory tests
RCT: 2 (1842)26-30 Insufficient Medium study limitations,
inconsistent, indirect,
imprecise
Differences ranged from 0.15 (95% CI, −0.96 to 1.26)
to −1.60 (95% CI, −2.55 to −0.65) tests
Costs of
laboratory tests
RCT: 3 (2050)26-30,32,33 Insufficient Medium study limitations,
inconsistent, indirect,
imprecise
Differences ranged from CaD$15 (95% CI,




RCT: 3 (1552)25,27,32,33 Insufficient Medium study limitations,
inconsistent, direct,
imprecise
Mean difference ranged from −0.7 (95% CI, NR or




Insufficient High study limitations,
inconsistent, direct,
imprecise
Adjusted OR ranged from 0.89 (95% CI, 0.86 to 0.93)
to 1.09 (95% CI, 1.04 to 1.15); mean difference (1
study), 0.04 (95% CI, −0.04 to 0.12), P = .35
Costs of emergency
department visits
RCT: 2 (996)27,32,33 Insufficient Medium study limitations,
consistency unknown,
direct, imprecise
Mean difference ranged from −$52 (95% CI, NR or not




Insufficient High study limitations,
consistency unknown,
direct, imprecise
Difference ranged from −$16.00 (95% CI, −$35.37 to
$2.96) to −$12.80 (95% CI, −$0.14 to $25.76)
No. of
hospitalizations
RCT: 3 (2208)25-30 Low for no benefit Medium study limitations,
consistent, direct, precise
Mean difference, 0.037 (95% CI, −0.006 to 0.080)
Cohort: 1 (4500)43 Low for benefit High study limitations,
consistency unknown,
direct, precise




RCT: 1 (556)25 Insufficient Low study limitations,
consistency unknown,
direct, imprecise
OR for MTM basic vs usual care, 2.069 (95% CI, 1.104
to 3.878), P = .02; OR for MTM enhanced vs usual
care, 1.345 (95% CI, −0. 693 to 2.609), P = .38
Cohort: CHF, COPD, or
unspecified: 3 (range,
795-200 722)37,41,56;








imprecise; and high study
limitations, consistency
unknown, direct, precise
Adjusted OR for CHF, COPD, or unspecified ranged
from 0.90 (95% CI, 0.87 to 0.94) to 1.4 (95% CI, 1.1
to 2.0); adjusted OR for diabetes ranged from 0.91
(95% CI, 0.87 to 0.95) to 0.93 (95% CI, 0.88 to 0.98)
(continued)
Medication Therapy Management Interventions Original Investigation Research
jamainternalmedicine.com JAMA Internal Medicine January 2015 Volume 175, Number 1 83
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
Copyright 2015 American Medical Association. All rights reserved.
Discussion
Evidence was insufficient to draw conclusions about the ef-
fect of MTM on most of the outcomes that we evaluated. We
assigned grades of low strength of evidence for either a ben-
efit (some measures of drug-therapy problems and health care
use) or a lack of benefit (patient satisfaction and health-
related quality of life) to few evaluation outcomes. The de-
gree to which identifying and resolving drug therapy prob-
lems translate into consistent, detectable improvements in
biomarkers of morbidity, health, patient experience, use, and
costs cannot be determined from this body of evidence.
Although we tried to capture a range of contexts and set-
tings and fill gaps by including observational studies, we did
not find credible, consistent evidence that MTM improved out-
comes globally regardless of study design. We included a very
large retrospective cohort study of Medicare Part D MTM pro-
grams operating in 2010.41 This evaluation focused on benefi-
ciaries with congestive heart failure, chronic obstructive pul-
monary disease, and diabetes. The authors reported that,
although uptake of and adherence to evidence-based medi-
cation improved for patients with congestive heart failure or
diabetes, these improvements did not consistently translate
to fewer condition-specific hospitalizations and emergency
department visits.41
Overall, we rated the MTM evidence base as insufficient,
even though some studies evaluated important outcomes and
had low or moderate risk of bias. Our assessment was often
based on inconsistency in the magnitude or direction of ef-
fect. Inconsistent effects of the intervention, as well as poor
measures, could explain inconsistent results.
For example, clinically effective MTM can either increase
or decrease health care use and expenditures based on the
needs of the patient. The goal of MTM overall is to optimize
pharmacotherapy and reduce unnecessary health care use, but
for patients who need more care, MTM could optimize phar-
macotherapy while increasing necessary health care use.
Future studies will benefit from better outcome measures.
In addition, analyses should take into account whether increases
in health care use are appropriate and whether identified inap-
propriate use can be attributed to overuse or underuse. Studies
often used nonstandardized measures for outcomes, such as ad-
verseevents,adherence,andexpendituresorcosts;thistendency
limited our ability to meta-analyze results.
Included MTM studies were largely practice based; they
varied substantially in usual-care comparators, specific inter-
vention elements, and patient populations. Standard medi-
cal care usually involves varying degrees of MTM-like ser-
vices from the patient’s prescribing providers and health care
teams. This reality is problematic for systematic reviews be-
cause MTM effectiveness in relationship to usual care can be
adequately characterized only by controlling for the varia-
tion in the active intervention components that might also be
present in the usual-care group.72
For MTM, this variation in practice likely reflects the evo-
lution of the professional practice of pharmacy. Most studies
were not designed to capitalize on variants in MTM program
elements for a rigorous, prospective evaluation of outcomes
by those variants. In addition, most studies did not report pa-
tient characteristics beyond age and sex, thus limiting our abil-
ity to address the underlying heterogeneity in our review. Fi-
nally, most studies did not measure fidelity to intended MTM
intervention elements; thus, whether studies demonstrating















Cohort: 1 (5717)60 Low for benefit High study limitations,
consistency unknown,
direct, precise
Adjusted HR, 0.55 (95% CI, 0.39 to 0.77)
Costs of
hospitalization
RCT: 3 (2050)26-30,32,33 Insufficient Medium study limitations,
inconsistent, direct,
imprecise
Inconsistent direction, consistent lack of effect: mean
difference in costs for MTM vs usual care, $2402; P
value reported as NS at .05 level in 1 study32,33;
−$221.00 (95% CI, −$566.33 to $124.33) in second
study26,28-30; mean difference in costs in third study:
CaD$159.74 (95% CI, −CaD$281.99 to
CaD$601.47)27
Cohort,
CHF: 1 (169 099)41
Insufficient High study limitations,
consistency unknown,
direct, imprecise
Risk-adjusted costs of condition-specific




Insufficient High study limitations,
consistency unknown,
direct, imprecise
Risk-adjusted costs of condition-specific




Low for benefit High study limitations,
consistency unknown,
direct, precise
Risk-adjusted costs of condition-specific
hospitalization for diabetes, −$363.45 (95% CI,
−$562.00 to −$164.91); all hospitalization costs




RCT: 1 (208)32,33 Insufficient Low study limitations,
consistency unknown,
direct, imprecise
MTM reduced length of stay by 1.8 d (6.7 vs 4.9 mean
hospital days for MTM vs usual care)
Abbreviations: CaD$, Canadian dollars; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; MTM, medication therapy
management; NR, not reported; NS, not significant; NRCT, nonrandomized clinical trial; OR, odds ratio; RCT, randomized clinical trial.
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no effect of MTM were actually failures of implementation is
difficult to determine.
Our findings emphasize several important needs for fu-
ture efforts to review MTM programs systematically. The first
is for researchers and program evaluators to specify and de-
sign MTM interventions based on existing definitions, taxono-
mies, and service models. The second is to use the appropri-
ate consensus guidelines for study reporting based on
design,73-76 giving particular attention to reporting interven-
tion features, usual care practices, and fidelity of interven-
tion delivery.77 Progress on these steps would enable system-
atic reviews of MTM services to better differentiate between
various types of services, different levels of intervention fi-
delity, and heterogeneous comparison groups.
Medication therapy management is already in wide-
spread practice, which presents both challenges and oppor-
tunities for researchers and policy makers. The MTM pro-
grams of the future may contribute to coordinated and
improved care through delivery within accountable-care or-
ganizations or patient-centered medical homes. However, as
MTM becomes more integrated into routine health care, the
more difficult it is to attribute change to MTM alone. Further-
more, secular trends in related quality-improvement initia-
tives (eg, medication adherence interventions; practice-
based, medication-related patient safety initiatives or
requirements; and meaningful use requirements for elec-
tronic health records) might obscure the effects of MTM ef-
forts. Positive deviance analyses78 with rigorous measure-
ment of implementation features or stepped wedge trial
designs79 may be useful, since they provide rigorous ap-
proaches to evaluating real-world implementation. Finally, the
population effect of MTM may depend on higher rates of pa-
tient participation; future studies and evaluations should con-
sider including measures of reach and examine alternative ways
of enrolling patients and keeping them engaged.
Study Limitations
Because MTM services vary substantially, any constraints ap-
plied by a systematic review to establish scope necessarily limit
the applicability of the review findings. Our review did not ad-
dress MTM interventions conducted in inpatient settings or
single-episode types of interventions (eg, medication recon-
ciliation, which some view as a specific type of MTM service).
Although we tried to distinguish MTM from disease or case
management interventions, making this distinction was chal-
lenging. We allowed MTM interventions that targeted pa-
tients with a single condition, such as diabetes or hyperten-
sion, as long as the MTM services included a comprehensive
review of all medications rather than just medications for the
single condition. Despite these limitations, the range of in-
cluded study designs enhanced the applicability of findings for
real-world settings when evidence was sufficient.24
We included interventions labeled pharmaceutical care
or medicines management to ensure that the evidence base
included studies before the Medicare Part D MTM era and
non-US studies. Although our approach made results more
challenging to interpret because of the resultant heteroge-
neity, it ensured that we captured interventions that had
MTM components but lacked the descriptor phrase medica-
tion therapy management. We attempted to stratify findings
by whether the study was a Part D program, but we did not
have enough studies that used the same outcomes to be
able to draw conclusions.
Future Research
New research should be based on national priorities. Studies
designed to identify causal relationships between MTM
inter ventions and their outcomes (including cost-
effectiveness analyses) must control for confounding, but
they may offer limited information on the elements that
explain program success or failure. Studies designed to
explore the reasons for program success or failure using
qualitative or single-arm designs may offer hypotheses-
generating rather than hypotheses-confirming insights on
MTM effectiveness. New research, regardless of specific
focus, will likely continue to find inconsistent results until
studies account for underlying sources of variability in
populations, interventions, and outcome measures.
Conclusions
We found a low strength of evidence of benefit for a limited
number of intermediate and health care use and cost out-
comes. Evidence was insufficient for most outcomes because
of inconsistency in direction and magnitude and also be-
cause of imprecision. Wide variations in populations and MTM
interventions likely explain these inconsistencies.
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